MWNA
VRDN icon

Marshall Wace North America’s Viridian Therapeutics VRDN Stock Holding History

Marshall Wace North America’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.23M Buy
+75,000
New +$1.1M 0.01% 858
2018
Q2 		– Sell
-807
Closed -$85K – 1711
2018
Q1 		$85K Buy
+807
New +$87.7K ﹤0.01% 1372

Other funds holding VRDN

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Marshall Wace North America's VRDN Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Viridian Therapeutics (VRDN) in Q3 2021: 75,000 shares worth $1.23M. The stake represents 0.01% of the portfolio and ranks #858 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in VRDN as recently as Q1 2018.

Marshall Wace North America first reported a position in VRDN in Q1 2018 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold VRDN as of Q3 2021.

  • Marshall Wace North America held 75,000 shares of Viridian Therapeutics worth $1.23M as of Q3 2021.
  • Viridian Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Viridian Therapeutics made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #858 holding.
  • Marshall Wace North America first reported a position in Viridian Therapeutics in Q1 2018 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.